Positive inotropic and lusitropic effects of HNO/NO− in failing hearts: Independence from β-adrenergic signaling
暂无分享,去创建一个
D. Kass | D. Wink | H. Champion | N. Paolocci | J. Fukuto | K. Miranda | T. Katori | Marcus E St John | Marcus E. St. John
[1] Pawan K. Singal,et al. Oxidative stress and heart failure , 1995, Molecular and Cellular Biochemistry.
[2] D. Kass,et al. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. , 2003, Free radical biology & medicine.
[3] J. Bronzwaer,et al. Myocardial contractile effects of nitric oxide. , 2002 .
[4] K. Houk,et al. The reduction potential of nitric oxide (NO) and its importance to NO biochemistry , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] N. Freemantle,et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.
[6] R. Bache,et al. Nitric Oxide Modulates Myocardial Oxygen Consumption in the Failing Heart , 2002, Circulation.
[7] R. Ventura-clapier,et al. Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. , 2002, Biochemical and biophysical research communications.
[8] Jun Peng,et al. The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. , 2002, European journal of pharmacology.
[9] A. Shah,et al. Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes , 2002, The Journal of physiology.
[10] Joao A. C. Lima,et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. , 2002 .
[11] D. Kass,et al. Imbalance Between Xanthine Oxidase and Nitric Oxide Synthase Signaling Pathways Underlies Mechanoenergetic Uncoupling in the Failing Heart , 2002, Circulation research.
[12] R. Maestri,et al. Chronic infusion of dobutamine and nitroprusside in patients with end‐stage heart failure awaiting heart transplantation: safety and clinical outcome , 2001, European journal of heart failure.
[13] D. Sane,et al. Upregulation of Functional &bgr;3-Adrenergic Receptor in the Failing Canine Myocardium , 2001, Circulation research.
[14] D. Kass,et al. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Kass,et al. Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] J. Balligand,et al. Upregulation of &bgr;3-Adrenoceptors and Altered Contractile Response to Inotropic Amines in Human Failing Myocardium , 2001, Circulation.
[17] D. Wink,et al. Unique Oxidative Mechanisms for the Reactive Nitrogen Oxide Species, Nitroxyl Anion* , 2001, The Journal of Biological Chemistry.
[18] B. Brenner,et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. , 2000, Clinical science.
[19] Alpar,et al. Neuropeptide variability in man , 2000, European journal of clinical investigation.
[20] D. Kass,et al. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. , 2000, Circulation research.
[21] T. Shinke,et al. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. , 2000, Circulation.
[22] D. Kass,et al. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. , 2000, Circulation.
[23] F. Gao,et al. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Balligand. Regulation of cardiac beta-adrenergic response by nitric oxide. , 1999, Cardiovascular research.
[25] E. Lakatta,et al. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. , 1999, Circulation research.
[26] R. Winslow,et al. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies. , 1999, Circulation research.
[27] I. Zucker,et al. Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. , 1999, Circulation research.
[28] J. Stamler,et al. NOS: Modulator, not mediator of cardiac performance , 1999, Nature Medicine.
[29] A. Franco‐Cereceda,et al. Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig. , 1998, Cardiovascular research.
[30] James B. Mitchell,et al. The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. , 1998, Archives of biochemistry and biophysics.
[31] M. Creager,et al. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. , 1998, Circulation.
[32] D. Kass,et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. , 1997, Journal of the American College of Cardiology.
[33] M. Redfield,et al. Angiotensin II in the evolution of experimental heart failure. , 1996, Hypertension.
[34] Y. Ishikawa,et al. β‐ADRENOCEPTOR DESENSITIZATION DURING THE DEVELOPMENT OF CANINE PACING‐INDUCED HEART FAILURE , 1996, Clinical and experimental pharmacology & physiology.
[35] M. Creager,et al. Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. , 1994, Journal of the American College of Cardiology.
[36] M. Feldman,et al. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. , 1993, Journal of the American College of Cardiology.
[37] M. Komajda,et al. Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. , 1992, European heart journal.
[38] C. Gennari,et al. Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. , 1990, Cardiovascular research.
[39] L. Opie. Drugs for the Heart , 1981 .